A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer
- PMID: 21989327
- DOI: 10.1093/annonc/mdr444
A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer
Abstract
Background: Eribulin mesylate is a non-taxane microtubule dynamics inhibitor that recently gained Food and Drug Administration approval for late-line metastatic breast cancer (MBC).
Patients and methods: In this single-arm, multicentre open-label phase II trial Japanese patients pretreated with an anthracycline and a taxane received 1.4 mg/m(2) eribulin mesylate (2- to 5-min i.v. infusion on days 1 and 8 of a 21-day cycle). The primary efficacy end point was overall response rate (ORR) by independent review.
Results: Patients (N = 80) had received a median of three prior chemotherapy regimens (range 1-5). ORR was 21.3% [95% confidence interval (CI) 12.9-31.8; all partial responses (PRs)], stable disease (SD) occurred in 30 patients (37.5%) and the clinical benefit rate (complete response + PR + SD ≥6 months) was 27.5% (95% CI 18.1-38.6). Median duration of response was 3.9 months (95% CI 2.8-4.9), progression-free survival was 3.7 months (95% CI 2.0-4.4) and overall survival was 11.1 months (95% CI 7.9-15.8). The most frequent treatment-related grade 3/4 adverse events were neutropenia (95.1%), leukopenia (74.1%) and febrile neutropenia (13.6%). Grade 3 peripheral neuropathy occurred in 3.7% of patients (no grade 4).
Conclusions: Eribulin exhibited efficacy and tolerability in Japanese patients with heavily pretreated MBC.
Similar articles
-
Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.J Clin Oncol. 2009 Jun 20;27(18):2954-61. doi: 10.1200/JCO.2008.17.7618. Epub 2009 Apr 6. J Clin Oncol. 2009. PMID: 19349550 Clinical Trial.
-
Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.J Clin Oncol. 2010 Sep 1;28(25):3922-8. doi: 10.1200/JCO.2009.25.8467. Epub 2010 Aug 2. J Clin Oncol. 2010. PMID: 20679609 Clinical Trial.
-
Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance.Breast Cancer Res Treat. 2016 Jun;157(2):295-305. doi: 10.1007/s10549-016-3808-x. Epub 2016 Apr 28. Breast Cancer Res Treat. 2016. PMID: 27125669 Free PMC article. Clinical Trial.
-
Review on the clinical use of eribulin mesylate for the treatment of breast cancer.Expert Opin Pharmacother. 2016;17(4):589-600. doi: 10.1517/14656566.2016.1146683. Epub 2016 Feb 17. Expert Opin Pharmacother. 2016. PMID: 26809667 Review.
-
Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.Clin Ther. 2012 Jul;34(7):1467-73. doi: 10.1016/j.clinthera.2012.06.003. Epub 2012 Jun 25. Clin Ther. 2012. PMID: 22739019 Review.
Cited by
-
Combination chemotherapy with mitomycin C and methotrexate is active against metastatic HER2-negative breast cancer even after treatment with anthracycline, taxane, capecitabine, and vinorelbine.Springerplus. 2015 Jul 26;4:376. doi: 10.1186/s40064-015-1159-4. eCollection 2015. Springerplus. 2015. PMID: 26217553 Free PMC article.
-
Enriching cancer pharmacology with drugs of marine origin.Br J Pharmacol. 2020 Jan;177(1):3-27. doi: 10.1111/bph.14876. Epub 2019 Dec 23. Br J Pharmacol. 2020. PMID: 31621891 Free PMC article. Review.
-
Eribulin versus S-1 as first or second-line chemotherapy to assess health-related quality of life and overall survival in HER2-negative metastatic breast cancer (RESQ study): a non-inferiority, randomised, controlled, open-label, phase 3 trial.EClinicalMedicine. 2024 Jul 16;74:102715. doi: 10.1016/j.eclinm.2024.102715. eCollection 2024 Aug. EClinicalMedicine. 2024. PMID: 39109189 Free PMC article.
-
Eribulin in Heavily Pretreated Metastatic Breast Cancer Patients in the Real World: A Retrospective Study.Oncology. 2018;94 Suppl 1(Suppl 1):10-15. doi: 10.1159/000489063. Epub 2018 Jul 23. Oncology. 2018. PMID: 30036867 Free PMC article.
-
Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study.Invest New Drugs. 2017 Dec;35(6):791-799. doi: 10.1007/s10637-017-0486-4. Epub 2017 Jun 29. Invest New Drugs. 2017. PMID: 28660549 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials